Owlet (OWLT) investor relations material

Business overview and product innovation

• Offers a holistic pediatric health platform with a focus on safety and data-driven parental insights.

• Dream Sock, an FDA-cleared at-home medical device, uses pulse oximetry to monitor infants and alert parents.

• Recently launched the third-generation Dream Sight camera, integrating real-time vitals and video in the app.

• Holds the largest set of infant health data, supporting advanced insights for users.

• Maintains a competitive moat as the only FDA-cleared at-home monitor, with clearances in multiple countries.

Subscription and service expansion

• Transitioned from one-time hardware sales to a subscription model (Owlet360), launched early last year.

• Achieved 115,000 paying subscribers by Q1, with a 34% penetration rate among U.S. Dream Sock users.

• Subscription priced at $9.99, with plans to expand to non-English-speaking markets this year.

• Developing new camera features and leveraging AI-ready hardware for future software enhancements.

• Subscription margins are significantly higher than hardware, supporting multi-year customer relationships.

Growth, profitability, and operational focus

• Revenue grew 35% last year, with adjusted EBITDA profitability achieved.

• Current focus is on growing high-margin subscriptions and launching a telehealth service (Owlet OnCall).

• Telehealth pilot enables sharing of biometric data with pediatricians, aiming to reduce unnecessary ER visits.

• U.S. Dream Sock penetration is 11% of births, with some states above 20%; international penetration remains low but targeted.

• Revised 2024 guidance: $118–$122 million revenue (12–15% growth), 50–52% gross margin, $7–$9 million adjusted EBITDA.